[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Astrazeneca Plc (AZN)

Astrazeneca Plc (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

AstraZeneca's Oncology Portfolio Hides a Dependency Wall Street Hasn't Priced In

AstraZeneca (AZN) reports first-quarter 2026 earnings before the market opens on April 29, with analysts expecting $2.57 per share on revenue estimates that remain unavailable. The pharmaceutical giant faces a critical test as investors weigh the company's oncology momentum and pipeline productivity against near-term headwinds including the Farxiga loss of exclusivity in the U.S., China VBP pricing pressures, and elevated R&D spending—all while the stock trades below most key moving averages following a sharp miss last quarter.

AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines, with leading franchises in oncology, cardiovascular, renal...

Fundamentals

See More
  • Market Capitalization, $K 289,523,488
  • Shares Outstanding, K 1,550,908
  • Annual Sales, $ 58,739 M
  • Annual Income, $ 10,225 M
  • EBIT $ 13,743 M
  • EBITDA $ 19,476 M
  • 60-Month Beta 0.35
  • Price/Sales 4.95
  • Price/Cash Flow 14.50
  • Price/Book 5.97

Options Overview Details

View History
  • Implied Volatility 27.83% (-4.00%)
  • Historical Volatility 24.01%
  • IV Percentile 69%
  • IV Rank 56.45%
  • IV High 34.22% on 02/05/26
  • IV Low 19.54% on 08/14/25
  • Expected Move (DTE 15) 7.85 (4.24%)
  • Put/Call Vol Ratio 0.83
  • Today's Volume 1,343
  • Volume Avg (30-Day) 2,340
  • Put/Call OI Ratio 0.94
  • Today's Open Interest 82,748
  • Open Int (30-Day) 81,164
  • Expected Range 177.35 to 193.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $2.55
  • Number of Estimates 4
  • High Estimate $2.58
  • Low Estimate $2.51
  • Prior Year $2.18
  • Growth Rate Est. (year over year) +16.97%

Price Performance

See More
Period Period Low Period High Performance
1-Month
181.73 +1.91%
on 04/29/26
207.30 -10.66%
on 04/10/26
-3.22 (-1.71%)
since 03/27/26
3-Month
181.73 +1.91%
on 04/29/26
212.71 -12.93%
on 02/18/26
+0.02 (+0.01%)
since 01/29/26
52-Week
132.32 +39.96%
on 05/14/25
212.71 -12.93%
on 02/18/26
+41.78 (+29.13%)
since 04/29/25

Most Recent Stories

More News
Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca

Option exercise triggers $25M payment to Pinetree.

AZN : 185.20 (-0.79%)
AstraZeneca results: Q1 2026

Strong revenue growth and positive readouts from high-value NMEs reinforce confidence in 2030 ambition

AZN : 185.20 (-0.79%)
AZN.LN : 13,782.000 (+0.66%)
AstraZeneca's Oncology Portfolio Hides a Dependency Wall Street Hasn't Priced In

Barchart Research What to Expect from AZN Earnings AZN Generated April 28, 2026 Current Price $186.68 EPS Estimate $$2.57 Consensus Rating Moderate Buy Average Move 2.64% AstraZeneca's Oncology Portfolio...

AZN : 185.20 (-0.79%)
BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older

Approval based on KALOS and LOGOS Phase III trials demonstrating statistically significant and clinically meaningful benefits of AstraZeneca’s single-inhaler fixed-dose triple therapy compared with inhaled...

AZN : 185.20 (-0.79%)
AZN.LN : 13,782.000 (+0.66%)
SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

First-in-class SAPHNELO Pen now offers greater flexibility and convenience, reaching a wider group of patients

AZN : 185.20 (-0.79%)
AZN.LN : 13,782.000 (+0.66%)
Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD

Third positive pivotal Phase III clinical trial of AstraZeneca’s IL-33-targeting biologic further demonstrates its benefits in COPD

AZN : 185.20 (-0.79%)
AZN.LN : 13,782.000 (+0.66%)
Aprea Therapeutics Showcases Emerging Clinical Data for WEE1 Inhibitor APR-1051

Aprea Therapeutics (APRE) recently showcased positive preliminary Phase 1 data for its next-generation WEE1 inhibitor, APR-1051, highlighting early tumor reduction in biomarker-defined cancer

AZN : 185.20 (-0.79%)
ZNTL : 3.96 (-2.22%)
MRK : 110.95 (+0.84%)
APRE : 0.8190 (-2.14%)
IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer

IMFINZI plus IMJUDO combined with lenvatinib and TACE demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in embolization-eligible unresectable liver...

AZN : 185.20 (-0.79%)
AZN.LN : 13,782.000 (+0.66%)
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD

First-ever IL-33-targeting biologic to demonstrate statistically significant and highly clinically meaningful reductions in COPD exacerbations in two replicate Phase III clinical trials

AZN : 185.20 (-0.79%)
AZN.LN : 13,782.000 (+0.66%)
AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer

Joshua Jackson is joined by Gritty to take the body check off the ice.

AZN : 185.20 (-0.79%)
AZN.LN : 13,782.000 (+0.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition...

See More

Key Turning Points

3rd Resistance Point 192.83
2nd Resistance Point 189.91
1st Resistance Point 187.56
Last Price 185.20
1st Support Level 182.29
2nd Support Level 179.37
3rd Support Level 177.02

See More

52-Week High 212.71
Last Price 185.20
Fibonacci 61.8% 182.00
Fibonacci 50% 172.52
Fibonacci 38.2% 163.03
52-Week Low 132.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.